FDA Releases Draft Labeling Guidance for Biosimilar Products
Big Molecule Watch
SEPTEMBER 25, 2023
When information specific to the reference product is described in the biosimilar or interchangeable biosimilar product’s labeling (for example, data from clinical trials of the reference product in the ADVERSE REACTIONS and CLINICAL STUDIES sections), the reference product’s proper name should be used.
62 
Let's personalize your content